MX2014003983A - Metodo para diagnosticar la enfermedad de alzheimer (ad). - Google Patents

Metodo para diagnosticar la enfermedad de alzheimer (ad).

Info

Publication number
MX2014003983A
MX2014003983A MX2014003983A MX2014003983A MX2014003983A MX 2014003983 A MX2014003983 A MX 2014003983A MX 2014003983 A MX2014003983 A MX 2014003983A MX 2014003983 A MX2014003983 A MX 2014003983A MX 2014003983 A MX2014003983 A MX 2014003983A
Authority
MX
Mexico
Prior art keywords
specific antibodies
aggregates
disease
sample
diagnosing alzheimer
Prior art date
Application number
MX2014003983A
Other languages
English (en)
Inventor
Walter Schmidt
Frank Mattner
Günther Staffler
Andreas Mairhofer
Martina Lutterova
Achim Schneeberger
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of MX2014003983A publication Critical patent/MX2014003983A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

La presente invención se relaciona con un método para diagnosticar la enfermedad de Alzheimer (AD), en donde se detectan los anticuerpos Aß específicos en una muestra biológica de una persona que se sospecha que tiene AD, que comprende las siguientes etapas: - poner en contacto la muestra con los agregados Aß o con partículas que tienen superficies similares al agregado Aß y que permiten que los anticuerpos Aß específicos se unan a los agregados Aß, y - detectar los anticuerpos Aß específicos unidos a los agregados Aß mediante una técnica de detección de partícula simple, de preferencia por clasificación celular activada por fluorescencia (FACS); y en donde la cantidad de anticuerpos Aß específicos detectados se compara con la cantidad en una muestra de estado AD conocido.
MX2014003983A 2011-10-04 2012-09-20 Metodo para diagnosticar la enfermedad de alzheimer (ad). MX2014003983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11183842.1A EP2579042B1 (en) 2011-10-04 2011-10-04 Method for detecting Aß-specific antibodies in a biological sample
PCT/EP2012/068493 WO2013050248A1 (en) 2011-10-04 2012-09-20 Method for diagnosing alzheimer's disease (ad)

Publications (1)

Publication Number Publication Date
MX2014003983A true MX2014003983A (es) 2014-05-07

Family

ID=46888451

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003984A MX2014003984A (es) 2011-10-04 2012-09-20 Metodo para detectar anticuerpos a-beta especificos en una muestra biologica.
MX2014003983A MX2014003983A (es) 2011-10-04 2012-09-20 Metodo para diagnosticar la enfermedad de alzheimer (ad).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014003984A MX2014003984A (es) 2011-10-04 2012-09-20 Metodo para detectar anticuerpos a-beta especificos en una muestra biologica.

Country Status (24)

Country Link
US (2) US9625459B2 (es)
EP (3) EP2579042B1 (es)
JP (2) JP6162127B2 (es)
KR (2) KR20140073568A (es)
CN (2) CN103842825B (es)
AR (1) AR088108A1 (es)
AU (2) AU2012320767A1 (es)
BR (2) BR112014008089A2 (es)
CA (2) CA2850840A1 (es)
CY (1) CY1115624T1 (es)
DK (2) DK2579042T3 (es)
ES (2) ES2496341T3 (es)
HK (1) HK1178601A1 (es)
HR (1) HRP20140937T1 (es)
IL (2) IL231057A0 (es)
MX (2) MX2014003984A (es)
PL (2) PL2579042T3 (es)
PT (1) PT2579042E (es)
RS (1) RS53496B1 (es)
RU (2) RU2014117671A (es)
SG (2) SG11201400229XA (es)
SI (1) SI2579042T1 (es)
SM (1) SMT201400145B (es)
WO (2) WO2013050249A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2787347A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP2787349A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
KR101658620B1 (ko) * 2014-12-02 2016-09-23 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
KR20170108203A (ko) 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
KR101871895B1 (ko) * 2016-04-20 2018-06-28 한국과학기술연구원 응집 단백질의 고감도 광 산화 증폭 면역 분석을 통한 체액기반의 퇴행성 신경질환 진단 방법
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
KR101989383B1 (ko) * 2017-04-04 2019-06-14 조선대학교산학협력단 알츠하이머성 치매의 조기진단을 위한 펩타이드 프로브
KR102108171B1 (ko) * 2018-08-27 2020-05-08 광주과학기술원 알츠하이머성 치매 진단용 펩타이드 바이오마커
WO2020045962A1 (ko) * 2018-08-27 2020-03-05 광주과학기술원 알츠하이머성 치매 진단용 펩타이드 바이오마커
CN113063949A (zh) * 2021-03-23 2021-07-02 中国医学科学院输血研究所 一种血浆中特异性IgM抗体的定量测定方法
CN113075398A (zh) * 2021-03-23 2021-07-06 中国医学科学院输血研究所 一种血浆中特异性IgG抗体的定量测定方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1996012544A1 (en) * 1994-10-19 1996-05-02 The General Hospital Corporation A DIAGNOSTIC ASSAY FOR ALZHEIMER'S DISEASE: ASSESSMENT OF Aβ ABNORMALITIES
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1792991A1 (en) * 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
WO2004074837A1 (en) * 2003-02-24 2004-09-02 Digitalbiotech Co., Ltd. Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer’s disease using same
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
DE102005006217B4 (de) * 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
JP4937143B2 (ja) * 2005-03-05 2012-05-23 アボット ゲーエムベーハー ウント カンパニー カーゲー 非拡散性球状Ａβ（Ｘ−３８．．４３）オリゴマー構造エピトープに対して特異性を有する自己抗体を検出する方法
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
RU2444356C2 (ru) * 2005-07-08 2012-03-10 Мартек Байосайенсиз Корпорейшн Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией
EP2808032B1 (en) * 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
JP2010515717A (ja) * 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
US7771957B2 (en) * 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
WO2009051599A1 (en) * 2007-10-19 2009-04-23 The Regents Of The University Of California Use of biomarkers of alzheimer's disease for diagnostic tests and drug screening
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
RU2011100127A (ru) 2008-06-12 2012-07-20 Аффирис Аг (At) Соединение, содержащее пептид, для лечения симптомов болезни паркинсона
CA2753586A1 (en) * 2009-02-24 2010-09-02 Winton G. Gibbons Detection of complexes of tau and amyloid
WO2010128139A1 (en) 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
JP2013521233A (ja) 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング

Also Published As

Publication number Publication date
BR112014008089A2 (pt) 2017-04-18
CY1115624T1 (el) 2017-01-04
US9625459B2 (en) 2017-04-18
AU2012320766B2 (en) 2017-09-21
DK2579042T3 (da) 2014-07-21
US20140234877A1 (en) 2014-08-21
SG11201400229XA (en) 2014-05-29
AU2012320766A1 (en) 2014-03-13
EP2764367B1 (en) 2018-07-25
SMT201400145B (it) 2014-11-10
RU2014117671A (ru) 2015-11-10
HK1178601A1 (en) 2013-09-13
US20140242727A1 (en) 2014-08-28
RS53496B1 (en) 2015-02-27
EP2764367A1 (en) 2014-08-13
PT2579042E (pt) 2014-09-09
KR20140069346A (ko) 2014-06-09
SI2579042T1 (sl) 2014-09-30
HRP20140937T1 (hr) 2014-12-05
PL2764367T3 (pl) 2019-04-30
KR20140073568A (ko) 2014-06-16
CN103842825A (zh) 2014-06-04
EP2579042B1 (en) 2014-07-09
WO2013050249A1 (en) 2013-04-11
EP2764368A1 (en) 2014-08-13
CA2850840A1 (en) 2013-04-11
ES2496341T3 (es) 2014-09-18
JP6162127B2 (ja) 2017-07-12
CA2850843A1 (en) 2013-04-11
PL2579042T3 (pl) 2014-12-31
EP2579042A1 (en) 2013-04-10
CN103842824A (zh) 2014-06-04
IL231057A0 (en) 2014-03-31
DK2764367T3 (en) 2018-10-29
WO2013050248A1 (en) 2013-04-11
ES2692185T3 (es) 2018-11-30
SG11201400223SA (en) 2014-05-29
RU2014117677A (ru) 2015-11-10
BR112014008088A2 (pt) 2017-04-18
CN103842825B (zh) 2016-04-20
JP2014529088A (ja) 2014-10-30
MX2014003984A (es) 2014-05-07
JP2014529087A (ja) 2014-10-30
AU2012320767A1 (en) 2014-03-13
IL231620A0 (en) 2014-05-28
AR088108A1 (es) 2014-05-07

Similar Documents

Publication Publication Date Title
MX2014003983A (es) Metodo para diagnosticar la enfermedad de alzheimer (ad).
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
WO2009037659A3 (en) Magnetic detection of small entities
NZ602056A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011109372A8 (en) Ultra-sensitive detection of molecules using dual detection methods
TR201818881T4 (tr) Sinyal Amplifikasyonu İmmünodeneyleri
MX2008006945A (es) Biosensor de deteccion de patogeno.
WO2013165615A3 (en) Methods, systems, and devices for detecting and identifying microorganisms in microbiological culture samples
MX2012004833A (es) Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
AU2012356133A8 (en) A rapid quantitative assay to measure CFTR function in a primary intestinal culture model
TN2014000120A1 (en) Cd27l antigen binding proteins
WO2011088014A3 (en) Systems and methods for counting cells and biomolecules
TW200801202A (en) Alpha-enolase specific antibody and method of use
EA201390638A8 (ru) Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения
EP3009454A3 (en) Antibodies specific to cadherin-17
WO2013055142A3 (ko) 두 종 입자를 이용한 다기능 생체물질 접합체의 제조방법 및 이로부터 제조된 다기능 생체물질 접합체
WO2013072842A8 (en) Long rigid spacers to enhance binding kinetics in immunoassays
NZ605449A (en) Anti-neuropilin antibodies and methods of use
MX2009010751A (es) Composiciones y metodos de deteccion.
EP2569635A4 (en) METHODS OF DIAGNOSING AND TREATING ENCEPHALITY OR EPILEPSY
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2007067984A3 (en) Neutralizing antibodies against primate psgl-1 and uses therefor
WO2010032899A3 (en) Eno1-specific human antibody
MX347247B (es) Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal